Synopsys Beats Q2, Raises FY26 Guide on Cost Discipline and Synergies

What happened

Synopsys reported Q2 FY26 revenue of $2.276B, above guidance, driven by strong performance and an EPS-neutral Ansys accounting impact. GAAP EPS was just $0.09 due to ~$404M quarterly amortization and restructuring, but non-GAAP EPS hit $3.35, reflecting strong cost discipline and accelerating synergies. Management raised full-year revenue guidance to $9.665B and non-GAAP EPS to $14.76, citing expanded margins and the impending close of the Processor IP sale. However, the company still hasn't quantified joint-solution revenue or cross-sell metrics, leaving the strategic platform thesis unverified. The planned September investor day offers a chance for management to provide proof points, but until then, the stock remains an execution story with high leverage.

Implication

The Q2 beat and raised guidance confirm that cost discipline and synergies are tracking well, but the core investment thesis hinges on proving that the Ansys combination generates measurable commercial lift beyond simple consolidation. GAAP earnings remain deeply negative due to amortization and interest, meaning that 35.8x EV/EBITDA pricing assumes a smooth path to margin recovery that has yet to materialize in reported numbers. With backlog conversion still the primary near-term anchor, investors should watch for any slippage in the ~47% 12-month conversion rate when Q3 RPO is disclosed. The raised non-GAAP EPS guidance is encouraging, but the gap between GAAP and non-GAAP profitability (fueled by $404M quarterly amortization) means that cash flow quality and net debt reduction remain critical to de-risk the balance sheet. Until management provides quantified joint-solution revenue or attach rates—potentially at the September investor day—the stock should be sized as a wait or trim above $480, with a disciplined entry near $395.

Thesis delta

The Q2 results modestly de-risk the near-term execution path on cost and revenue, but they do not alter the fundamental need for proof of cross-sell and integrated platform benefits. The raised guidance and cost discipline improve confidence in the non-GAAP margin outlook, but the thesis remains in a 'show me' phase—without quantified joint-solution metrics, the stock's multiple expansion from here is unjustified. We maintain our WAIT rating with a $480 trim level and $395 attractive entry, pending clearer evidence of commercial traction from the combined portfolio.